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Summary. Cefotiam hexetil is a pro-drug of cefotiam 
available for oral administration. To evaluate cefotiam 
concentrations at the active site in skin and soft-tissue in- 
fections, drug levels in skin suction blister fluid (SBF), 
cantharides blister fluid (CBF) and serum were deter- 
mined. Six healthy subjects received oral cefotiam 400 mg 
as cefotiam hexetil. On an other day 200 mg was injected 
intravenously. 
Following the oral dose, the bioavailability of cefotiam 
was 45.5%, and the maximum concentration i  serum of 
2.6mg-1 -~ was obtained at 2.1 h. Peak concentrations 
in both types of blister fluid (0.9 mg. 1-1) were significant- 
ly lower than after the iv dose (SBF 1.4 mg.1 -I, CBF 
1.5 mg. 1 - 1), and the peak levels occurred later (3.3 versus 
1.5 h in CBF). Despite the delay, the extent of penetration 
was about 100% following either mode of administration 
(SBE iv dose 112%, oral dose 117%). The cefotiam level 
in skin blister fluids declined significantly more slowly 
than the serum level. Following the oral dose, the mean 
terminal half life was serum 0.8 h, SBF 2.6 h and CBF 
4.6h. 
Cefotiam concentrations in the blister fluids were 
close to the MIC90 of Staphylococcus aureus, S. epidermis 
and H. influenzae and exceeded the MIC90 of Streptococ- 
ci, E. coli and Proteus mirabilis. 
Thus, the oral administration ofcefotiam 400 mg t. i. d. 
should be curative in the majority of bacterial infections of 
the skin and soft-tissues. 
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Second generation cephalosporins, such as cefotiam, are 
highly active against common gram-negative aerobic or- 
ganisms [1]. And, in contrast to many third generation ce- 
phalosporins, cefotiam also inhibits gram-positive cocci 
[2]. The broad spectrum of second generation cephalospo- 
rins makes them candidates for the treatment of skin and 
soft-tissue infections in which mixed bacterial coloniza- 
tion may occur [3]. Moreover, the severity of such diseases 
may require instantaneous treatment before the micro- 
organism has been cultured. 
The need for repeated parenteral administration has 
restricted the use of new cephalosporins in out-patients 
[4], so cephalosporin esters suitable for oral administra- 
tion (such as cefotiam hexetil or cefuroxime axetil) [5-7] 
have been developed. During absorption, the ester is hy- 
drolysed and the active agent is released [5, 8]. In a first 
clinical study, cefotiam hexeti1300-600 rag/day was effec- 
tive in 87% patients uffering from bacterial infection of 
the skin (Kumazawa J, 1987 unpublished data). Cure rates 
exceeding 90% were reported with cefuroxime axetil [6] 
and cefaclor [6, 9, 10] 0.5-2.0 g/day. 
To study cefotiam concentrations at the site of bacteri- 
al infections in skin and soft-tissue infections following 
cefotiam hexetil (SCE2174), skin blister fluid [11, 12] and 
serum levels have been determined in healthy volunteers. 
The drug levels following a single oral dose have been 
compared to those after an intravenous injection. 
Material and methods 
Subjects 
Six healthy subjects (5 male, 1 female, aged 23-35 y, weight 60- 
90 kg, height 173-200 cm) participated inthe experiments after giv- 
ing written informed consent to it. The subjects refrained from tak- 
ing other drugs, alcohol and caffeine. 
Protocol 
The study followed a randomized, cross-over design. During the 
preceding night of cefotiam and cefotiam hexetiI administration 
food intake was not allowed. The subjects received one oral dose of 
400 mg cefotiam as cefotiam hexetil (2 tablets of 200 rag) and one iv 
injection (200 mg) of cefotiam dihydrochloride (Spizefe; injection 
period 3 min; end of infusion was taken as 0 time point). Both prepa- 
rations were supplied by Takeda Pharma, Stolberg, FRG. The drugs 
were administered together with breakfast. The washout period be- 
tween the administrations was 7 days. Blood samples to provide 
serum were taken before drug administration, and after 5, 10, 20, 30, 
and 45 min as well as 1, 1.5, 2, 2.5, 3, 4, 5, 6, and 8 h. Suction blister 
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Fig. 1. Cefotiam concentrations in serum (  9  SBF (  9  and CBF 
(0 )  following a single intravenous dose of 200 mg cefotiam in six 
healthy volunteers. Mean (SEM) 
fluid (SBF) and cantharides blister fluid (CBF) were obtained at 0.5, 
1, 2, 3, 4, and 6 h, and CBF at 1.5 and 8 h, too. The induction of can- 
tharides and suction blisters tarted 13 and 3 h before dosing. Details 
of the blistering procedures are given elsewhere [13, 14]. Serum and 
blister fluid samples were stored at - 20 ~ until analyzed. 
Drug assay 
Cefotiam was determined in serum, SBF and CBF by HPLC (E Kees 
et al., in preparation). In brief, serum and blister fluids were depro- 
teinized with acetonitrile, which was removed by extraction with di- 
chloromethane. 50gl of the aqueous phase (kept frozen until in- 
jected) were directly chromatographed using reversed-phase 
HPLC. The eluate was monitored at 254 nm. Linear esults were ob- 
tained in the range cefotiam 0.1 to 10 gg/ml; the relative standard e- 
viation was 3 to 7%. The method also allowed determination f the 
isomeric d3-cefotiam (detection limit 0.01-0.02 mg/1). 
Serum standards for the calibration graphs were prepared using 
blank human serum. Blister fluid standards were made in phosphate 
buffer pH 7.0. 
Protein binding 
Cefotiam binding in SBF and CBF was calculated as described by 
McNamara et al. [15], based upon serum binding of 40% [16] and the 
albumin concentration i  serum and skin blister fluids previously 
determined [13]. 
Pharmacokinetic calculations 
Maximum cefotiam concentrations (C~a• in serum, SBF and CBF, 
and the times to those maximum concentrations (tmax), were  ob- 
tained from the measured ata. The elimination rate constant (k) 
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was calculated from the terminal loglinear decline in concentration 
in the appropriate fluids. The areas under the cefotiam concentra- 
tion-time curves (AUC), serum clearance (C1), the volume of dis- 
tribution (Vz) and bioavailability of cefotiam following cefotiam 
hexetil were calculated. 
Drug penetration i to the skin blister fluids (Pen) was obtained 
as the area ratio blister fluid/serum based upon free drug levels. 
Statistical evaluation 
The data are expressed as the arithmetic mean (SEM). They were 
evaluated statistically using the Wilcoxon test for tied pairs. P < 0.05 
was considered as significant. 
Results 
Intravenous dose 
Mean serum and bl ister fluid concentrat ions of cefot iam 
are depicted in Fig. 1. The max imum concentrat ion in 
serum was 16.2 rag-1-1 and the cefot iam level had de- 
cl ined to 0.078 (0.004) mg. 1-1 at 4 h. The mean terminal  
half life of the serum level was 0.8 h (Table 1). P lasma 
clearance amounted to 31.8 (1.8) 1. h -1 and the volume of 
distr ibut ion was 0.35 (0.002) 1. kg -1. 
The max imum concentrat ions of 1.4 mg.1-1 in SBF 
and 1.5 mg. 1-1 in CBF were obta ined after 1.0 and 1.5 h, 
respectively. Thereafter,  the bl ister fluid levels exceeded 
the serum concentrat ion.  The mean concentrat ion i the 
bl ister fluids decl ined to SBF 0.28 (0.03) and CBF  0.56 
(0.03) mg.  1 - 1 at 6 h and the mean terminal  half l ives were 
2.3 h in SBF and 3.5 h in CBF, thus signif icantly exceeding 
the serum half life. The fraction unbound of cefot iam was 
0.775 in SBF and 0.635 in CBE Thus, cefot iam penetrat ion  
into SBF and CBF  amounted  to 112 and 151%, respecti-  
vely. 
The serum concentrat ion of d3-cefot iam was below 
the detect ion l imit in four subjects and was up to 
0.061 mg. 1- ] in the others. In all volunteers,  d3-cefot iam 
in CBF  was always below the detect ion limit. In SBF 
minor  concentrat ions of the metabol i te  were found in four 
volunteers ( < 0.045 mg. 1 1). 
Oral dose 
The mean cefot iam levels are shown in Fig. 2. The peak 
serum level of 2.6 mg. 1-1 occurred after 2.1 h. A t  4 and 6 h 
cefot iam concentrat ions were 0.59 (0.15) and 0.11 (0.03) 
mg. 1-1, respectively. 
The bioavai labi l i ty of cefot iam fol lowing oral inges- 
t ion of cefot iam hexeti l  was 45%. The terminal  half life 
was 0.8 h (Table 1). In SBF the mean peak concentrat ion 
of 0.9 mg-1-1 was obta ined at 3.5 h, and the corresponding 
values in CBF  were 0.9 mg. 1-1 and 3.3 h. The max imum 
concentrat ions in the bl ister fluids were significantly 
lower and the t ime to the peak  concentrat ions were signif- 
icantly pro longed as compared  to the iv dose. A t  6 h the 
cefot iam concentrat ion in SBF was 0.47 (0.05)mg-1-1, 
thus signif icantly exceeding the drug level fol lowing the iv 
dose. CBF  concentrat ions were 0.52 (0.05) and 0.30 
(0.06) mg. 1 1 at 6 and 8 h. The terminal  half lives in SBF 
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Table L Pharmacokinetics of cefotiam following single oral and iv doses of 400 and 200 mg; respectively (n; 6; ~ (SEM)) 
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Parameter Serum SBF CBF 
iv oral iv oral iv oral 
tmax[h] 0.083 a 2.1 (0.3) 1.0 3.5 (0.6) b 1.5 (0.2) 3.3 (0.3) b
C~ax[mg/1] 16.2 (8) a 2.6 (0.3) 1.4 (0.9) 0.9 (0.1) u 1.5 (0.1) 0.9 (0.1) 
tie [h] O.8 (0.06) 0.8 (0.08) 2.3 (0.3) c 2.6 (0.5) c 3.5 (0.4) c 4.6 (0.8) c
AUC [mg-l-lh] 6.4 (0.3) 5.8 (0.5) 5.5 (0.2) 5.3 (1.1) 9.0 (0.3) 6.3 (0.9) 
Pen[%] 112 (3) 117 (11) 151 (8) 114 (11) 
a first sampling time 5 min after administration; b p _< 0.05 versus iv administration; ~P < 0.05 versus erum 
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Fig.2. Cefotiam concentrations in serum ( 9  SBF (A) and CBF 
(0). Six healthy volunteers received asingle oral dose of 400 mg 
cefotiam as cefotiam hexetil. Mean (SEM) 
(2.6 h) and CBF (4.6 h) was in accordance with the corre- 
sponding values following the intravenous injection. 
Cefotiam penetration into SBF and CBF was 117 and 
114%, respectively. 
d3-Cefotiam was detected in serum samples from five 
subjects. The peak level (0.019 to 0.097 mg. I- 1) was found 
after 1 to 1.5 h. In four subjects d3-cefotiam was detect- 
able in CBF (0.010 to 0.045 mg. 1-1), and in SBF the maxi- 
mum d3-cefotiam level (0.051 to 0.099 mg.1-1) was ob- 
served 2 to 4 h after the dose of cefotiam. At 6 h the SBF 
level of d3-cefotiam was 0.045 (0.023) rag- 1-1. 
Discuss ion  
In a previous tudy serum and skin blister fluid levels of 
cefotiam were evaluated following a single intramuscular 
dose of i g. Drug penetration into the blister fluid was 
about 100%. SBF and CBF levels were well above the 
MIC of Neisseria gonorrhoeae, suggesting the suitability 
of a 1 g single-dose regimen of cefotiam for gonorrhoea 
[17, 18], as subsequently proven in a clinical trial [19]. In 
the present study, the SBF and CBF levels of cefotiam 
were lower than following i. m. administration [17], even 
after correction for the dose administered. 
Following the iv dose, cefotiam concentrations in
serum and the derived pharmacokinetic parameters were 
in accordance with those reported by Brisson et al [20], if 
corrected for the 200 mg dose. 
The isomer d3-cefotiam was found in very low concen- 
trations following the iv injection, but after cefotiam 
hexetil p.o. higher d3-cefotiam concentrations were ob- 
served in serum and blister fluids. This suggests i omeriza- 
tion of cefotiam during drug absorption. Isomerization 
has also been observed in homogenates of small intestine, 
liver and in plasma from mice [5]. d3-Cefotiam isdevoid of 
antibacterial ctivity [21]. 
Following cefotiam hexetil, the bioavailability of cefo- 
tiam was 45%, and its terminal half life was 0.8 h. The con- 
centrations of d3-cefotiam, cefotiam bioavailability and 
terminal half life are close to the data reported by Couet et 
al. [1987, unpublished ata]. The bioavailability of cefo- 
tiam is close to that of cefuroxime administered as cefu- 
roxime axetil (52%) [22] but is less than that of cefaclor 
availability ( > 65%) [23]. 
Levels in CBF have been evaluated following cefurox- 
ime i g im. The terminal half life in CBF (1.6 h) was con- 
sistent with the serum half life, and the maximum level in 
CBF was 12.6 mg/1 [12], which is close to the peak cefo- 
tiam level following 1 g im [17]. With cefotiam, however, 
the drug level in SBF and CBF declined more slowly than 
the serum concentration (Table 1). Such behaviour is fre- 
quently observed with drugs of high hydrophilicity and 
very rapid elimination [18]. Thus, cefotiam concentrations 
in both blister fluids exceeded the serum concentrations 
from about 4 h after the oral dose, and even 1 to 1.5 h after 
following the iv dose (Figs. 1, 2). Therefore, active concen- 
trations will persist in the skin and probably also in soft tis- 
sues for a longer period of time than in serum. 
No essential difference between cefotiam concentra- 
tions in SBF and CBF were observed. Following an oral 
dose, the penetration of cefotiam into SBF and CBF 
amounted to 117% and 114%, respectively, which means 
that tissue penetration was close to the 100% expected, if 
the free drug were homogeneously distributed between 
plasma and tissue fluid [18]. The inflammatory eaction of 
the tissues obtained by the induction of cantharides blis- 
ters, but not by suction blistering [13, 18], did not have a 
major influence on tissue penetration by cefotiam. 
Cefotiam only binds to a minor extent o serum pro- 
teins (serum 40%; SBF 22.5%). Therefore, MIC values 
are virtually not affected by the addition of serum to the 
incubation medium [24], and drug levels in blister fluids 
may be compared to in vitro activity without he need to 
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correct for protein binding. Following 400 mg p.o. and 
200 mg i.v., the peak concentrations of cefotiam in the 
blister fluids were close to the MICg0 values of Staphylo- 
coccus aureus, S. epidermidis and H. influenzae [2, 25, 26], 
and they exceeded the MIC90 values of Streptococcus 
pyogenes, S.pneumoniae, E. coli and Proteus mirabilis [2]. 
These organisms are frequently isolated from skin infec- 
tions [3]. It appears that the doses used in the investigation 
of cefotiam hexetil in skin infections (100-200 mg t.i.d.) 
were low, and increasing the dose should result in a higher 
cure rate, as described for cefuroxime axetil and cefaclor 
[6, 9, 10]. 
In conclusion, the present results suggest that cefotiam 
hexetil 400 mg t. i .d .p .o ,  should be curative in the ma- 
jority of skin and soft-tissue infections. Nevertheless, in 
severe cases, as well as in instances of treatment failure, in- 
creasing the daily dose would be advisable. 
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